Perrigo周四表示，将以最高1.75亿美元将其婴儿配方奶粉业务出售给私营合同制造商MeridianMade，这家消费者健康产品公司正更加专注于非处方药和自我保健产品。
以下是部分细节：此次交易是继Perrigo去年对婴儿配方奶粉业务进行战略评估之后进行的。
交易包括交割时支付的4000万美元现金，以及最高1.35亿美元与业务截至2030年业绩挂钩的额外付款。
Perrigo said on Thursday that it will sell its infant formula business to privately held contract manufacturing firm MeridianMade for up to $175 million, as the consumer health products company sharpens its focus on over-the-counter medicines and self-care products.
Perrigo预计交易将于2027年上半年完成。
Here are some details:
MeridianMade首席执行官罗恩·贝尔德格伦和总裁米娅·芬特此前共同创立了婴儿配方奶粉品牌ByHeart，该品牌在出现婴儿肉毒杆菌中毒报告后在全国范围内召回产品。
本月早些时候，Perrigo同意支付1000万美元了结一宗美国集体诉讼。
The transaction follows a strategic review of the infant formula business by Perrigo last year The deal includes $40 million in cash at closing and as much as $135 million in additional payments tied to business's performance through 2030 Perrigo expects the transaction to close in the first half of 2027 MeridianMade CEO Ron Belldegrun and President Mia Funt previously co-founded ByHeart, an infant formula brand that recalled its products nationwide after reports of infant botulism Earlier this month, Perrigo agreed to pay $10 million to settle a US class action.
该诉讼指控其与Gerber Products合谋将新竞争者排除在商店品牌婴儿配方奶粉市场之外，据称这使Perrigo得以提价，而零售商将涨价转嫁给消费者。
上周，雅培（ABT.N）宣布将剥离其营养业务，其中包括婴儿配方奶粉。
Perrigo的婴儿配方奶粉部门一直因生产质量和污染风险而受到审视。
The suit accused it of conspiring with Gerber Products to keep new competitors out of the store-brand infant formula market, which allegedly allowed Perrigo to raise prices that retailers passed on to consumers Last week, Abbott (ABT.N)announced that it is separating its nutrition business, which includes baby formulas Perrigo's infant formula unit has faced scrutiny over manufacturing quality and contamination risks